<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00700544</url>
  </required_header>
  <id_info>
    <org_study_id>LAM SA 2002</org_study_id>
    <nct_id>NCT00700544</nct_id>
  </id_info>
  <brief_title>Treatment Outcome in Elderly Patients</brief_title>
  <official_title>Adjonction of Androgenotheapy for Post-Remission Treatment of Elderly Patients With Acute Myeloid Leukemia - Results of the Multicenter Goelams SA-2002 Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BGMT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter randomized trial evaluating the possible benefit of androgens during post
      remission therapy in an attempt to improve the outcome of AML in older patients.All patients
      received the ICL regimen as induction and were randomized to receive, after achieving CR or
      PR, a maintenance therapy including or not androgens. Patients randomized with androgens
      additionally received 10 to 20 mg according to body weigh of norethandrolone daily for up to
      2 years
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Induction Therapy:

             -  Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1

             -  if CR or PR: randomisation = maintenance therapy including or not androgens

        -  Maintenance therapy :

             -  6 courses of reinduction with idarubicin (8mg/m2 d1) and cytarabine (100mg/m2d1-5,
                subcutaneously) every 3 months, and, between these courses, a continuous regimen of
                methotrexate and 6-mercaptopurine.

             -  Patients randomized with androgens additionally received 10 to 20 mg according to
                body weigh of norethandrolone daily for up to 2 years
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study was to assess the ability of androgens to increase DFS.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective was to improved EFS and OS and to assess side effects and toxicity of androgenotherapy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>AML</condition>
  <condition>Elderly Patients</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR
maintenance therapy every 3 months = 6 courses of reinduction with :
-idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5 ), subcutaneously
between the courses, a continuous regimen of methotrexate and 6-mercaptopurine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR
maintenance therapy every 3 months = 6 courses of reinduction with :
idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5, subcutaneously)
10 to 20 mg (according to body weigh) of norethandrolone daily
between the courses, a continuous regimen of methotrexate and 6-mercaptopurine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy treatment (see arm) + norethandrolone</intervention_name>
    <description>oral form
Dosage:
10 mg in patients with a weight &lt; 60 kgs 20 mg in patients with a weight &gt; 60 kgs frequency: every day Duration: 2 years</description>
    <arm_group_label>A</arm_group_label>
    <other_name>norethandrolone = nilevar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy treatment (see arms)</intervention_name>
    <description>Induction chemotherapy + maintenance chemotherapy</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Induction chemotherapy + maintenance chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 60 years or more

          -  &quot;de novo&quot; AML according to FAB criteria

          -  AML with 20% or more myeloid marrow blasts

          -  signed and dated informed consent

          -  OMS score &lt; 3

          -  Life expectancy &gt; 1 month

        Exclusion Criteria:

          -  Patients aged &lt; 60 years

          -  or AML M3

          -  or not classificated according to FAB criteria

          -  or extramedular localisation of AML

          -  OMS score ≥ 3

          -  clinical Abnormal Cardiac fonction or with left ejection fraction &lt; 40 %

          -  abnormal renal function with creatinine clearance &lt; 50/ml/mn/m²

          -  abnormal hepatic function

          -  previous cerebral stroke

          -  previous malignancy : prostate, breast cancer (males)

          -  PSA dosage &gt; 4

          -  Any coexisting medical or psychological condition that would pleclude participation in
             the required study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean jacques SOTTO, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GOELAMS/BGMT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnaud PIGNEUX, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>GOELAMS/BGMT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francis WITZ, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arnaud PIGNEUX</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <last_update_submitted>June 13, 2008</last_update_submitted>
  <last_update_submitted_qc>June 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>CHU Grenoble Pr Jean Jacques SOTTO</name_title>
    <organization>GOELAMS BGMT</organization>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>elderly patients</keyword>
  <keyword>Treatment outcome</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Norethandrolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

